{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:39:24Z","timestamp":1793176764228,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clgc.2024.01.002","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T20:36:36Z","timestamp":1704746196000},"page":"476-482.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bladder-Preserving Trimodality Therapy With Capecitabine"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9354-4223","authenticated-orcid":false,"given":"Connor","family":"Lynch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy F.","family":"Sweis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush K.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1444-3617","authenticated-orcid":false,"given":"Russell Z.","family":"Szmulewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-2527","authenticated-orcid":false,"given":"Walter M.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley L.","family":"Liauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Pitroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.01.002_bib0001","unstructured":"Cancer of the urinary bladder : cancer stat facts. SEER. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html Accessed May 20, 2023."},{"issue":"3","key":"10.1016\/j.clgc.2024.01.002_bib0002","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Powles","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.clgc.2024.01.002_bib0003","unstructured":"NCCN Bladder Cancer Guidelines v2.National Comprehensive Cancer Network.2023. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf.Accessed May 20, 2023."},{"issue":"1","key":"10.1016\/j.clgc.2024.01.002_bib0004","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3109\/00365599.2011.609835","article-title":"Long-term follow-up after radical cystectomy with emphasis on complications and reoperations: a Swedish population-based survey","volume":"46","author":"Liedberg","year":"2012","journal-title":"Scand J Urol Nephrol"},{"issue":"3","key":"10.1016\/j.clgc.2024.01.002_bib0005","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.eururo.2009.05.008","article-title":"Complications following radical cystectomy for bladder cancer in the elderly","volume":"56","author":"Froehner","year":"2009","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.01.002_bib0006","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12894-018-0402-z","article-title":"Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy","volume":"18","author":"Froehner","year":"2018","journal-title":"BMC Urology"},{"issue":"2","key":"10.1016\/j.clgc.2024.01.002_bib0007","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijrobp.2013.06.2044","article-title":"Randomized Noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK\/01\/004)","volume":"87","author":"Huddart","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.clgc.2024.01.002_bib0008","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.clgc.2024.01.002_bib0009","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"JCO"},{"issue":"5","key":"10.1016\/j.clgc.2024.01.002_bib0010","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ijrobp.2005.01.004","article-title":"A single institution experience with concurrent capecitabine and radiation therapy in weak and\/or elderly patients with urothelial cancer","volume":"62","author":"Patel","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clgc.2024.01.002_bib0011","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.clgc.2018.10.003","article-title":"Safety and efficacy of hypofractionated radiotherapy with capecitabine in elderly patients with urothelial carcinoma","volume":"17","author":"Leng","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2024.01.002_bib0012","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.31557\/APJCP.2022.23.5.1733","article-title":"Could concurrent capecitabine with hypofractionated radiotherapy in elderly patients with muscle-invasive bladder cancer be an option?","volume":"23","author":"Youssief","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"10.1016\/j.clgc.2024.01.002_bib0013","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chro Dis"},{"issue":"5","key":"10.1016\/j.clgc.2024.01.002_bib0014","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2024.01.002_bib0015","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), , CTEP. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50.Accessed March 18, 2023."},{"issue":"282","key":"10.1016\/j.clgc.2024.01.002_bib0016","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"JASA"},{"key":"10.1016\/j.clgc.2024.01.002_bib0017","unstructured":"R: a language and environment for statistical computing. https:\/\/www.R-project.org\/. Accessed January 10, 2023."},{"key":"10.1016\/j.clgc.2024.01.002_bib0018","unstructured":"Therneau TM, Elizabeth A, Cynthia C. Survival: survival analysis. Available at: https:\/\/cran.r-project.org\/web\/packages\/survival\/index.html Accessed August 3, 2023."},{"key":"10.1016\/j.clgc.2024.01.002_bib0019","unstructured":"Kassambara A, Kosinski M, Biecek P, Fabian S. survminer : drawing survival curves using \u201cggplot2\u201d Available at: https:\/\/cran.r-project.org\/web\/packages\/survminer\/index.html. Accessed August 3, 2023."},{"issue":"2","key":"10.1016\/j.clgc.2024.01.002_bib0020","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1038\/modpathol.2009.26","article-title":"Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications","volume":"22","author":"Amin","year":"2009","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.clgc.2024.01.002_bib0021","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.juro.2012.11.084","article-title":"Plasmacytoid Urothelial carcinomas : a chemo-sensitive cancer with poor prognosis, and peritoneal carcinomatosis","volume":"189","author":"Dayyani","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.01.002_bib0022","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s12935-020-01626-9","article-title":"Sarcomatoid variant urothelial carcinoma of the bladder: a systematic review and meta-analysis of the clinicopathological features and survival outcomes","volume":"20","author":"Gu","year":"2020","journal-title":"Cancer Cell Int"},{"issue":"6","key":"10.1016\/j.clgc.2024.01.002_bib0023","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Euro Urol"},{"issue":"34","key":"10.1016\/j.clgc.2024.01.002_bib0024","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.clgc.2024.01.002_bib0025","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2024.01.002_bib0026","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Eng J Med"},{"issue":"11","key":"10.1016\/j.clgc.2024.01.002_bib0027","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group","volume":"16","author":"Shipley","year":"1998","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2024.01.002_bib0028","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clgc.2021.03.007","article-title":"Trimodality therapy with or without neoadjuvant chemotherapy for muscle invasive bladder cancer","volume":"19","author":"Royce","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2024.01.002_bib0029","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732400003X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732400003X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:26:52Z","timestamp":1793176012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732400003X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S155876732400003X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.01.002","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bladder-Preserving Trimodality Therapy With Capecitabine","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}